Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, such as cancer.

Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.

Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.

Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.

Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.

Abstract: This invention relates to anti-NKG2A antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.

Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.

Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.

Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.

Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.

Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.

Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.

Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.

Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.

Abstract: A drug delivery device (100) for estimating the amount of free air in a cartridge (1) comprising a cartridge receiving portion (not shown) adapted to receive a cartridge (1), the cartridge (1) comprising a body portion (6), an axially displaceable piston (5), and a distal outlet portion (4), an expelling assembly comprising an axially displaceable piston drive member (10) adapted to interface with the proximal piston (5) portion of a received cartridge (1), the piston drive member (10) is adapted to be moveable in a distal direction, and to thereby pressurize the drug in a received cartridge. The drug delivery device further comprises means for measuring and acquiring a property relating to a fluid pres-sure of the drug in a received cartridge (1), and where the property depends on the amount of free air (7) contained in the cartridge (1).

Abstract: A drug delivery system comprising a controller adapted to detect when a given user-actuated operation being part of the expelling of an amount of drug is performed, record detected operations as a function of time, and estimate, based on recorded operations, time parameters for the detected operations, thereby providing time parameters for a medical regimen on which the detected operations are assumed to be based upon.

Abstract: A drug delivery system (1) comprising first (35) and second reservoir units (30) with first and second identifiers (32), and a main unit (10) adapted to receive either of the first (35) and second reservoir units (30) in a mounted position. The main unit (10) comprises drug expelling means having dose setting means (11, 1, 14, 15, 19) comprising a rotational dose setting member allowing a user to set a desired dose size for the given drug, the dose size being set in fixed increments for a given state. The drug expelling means has a first state in which an increment corresponds to a first volume of drug, and a second state in which an increment corresponds to a second volume of drug, wherein the drug expelling means is set in the first state by means of the first identifier when a first reservoir unit is mounted, and the drug expelling means is set in the second state by means of the second identifier when a second reservoir unit is mounted.